A detailed history of Geode Capital Management, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 841,725 shares of GALT stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
841,725
Previous 567,161 48.41%
Holding current value
$2.28 Million
Previous $1.36 Million 40.37%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$2.13 - $4.2 $584,821 - $1.15 Million
274,564 Added 48.41%
841,725 $1.9 Million
Q1 2024

May 13, 2024

BUY
$1.6 - $2.44 $84,392 - $128,697
52,745 Added 10.25%
567,161 $1.36 Million
Q4 2023

Feb 13, 2024

BUY
$1.6 - $2.18 $6,376 - $8,687
3,985 Added 0.78%
514,416 $853,000
Q3 2023

Nov 13, 2023

SELL
$1.38 - $1.97 $16,359 - $23,354
-11,855 Reduced 2.27%
510,431 $980,000
Q2 2023

Aug 11, 2023

BUY
$1.32 - $2.08 $802 - $1,264
608 Added 0.12%
522,286 $752,000
Q1 2023

May 15, 2023

BUY
$1.1 - $2.4 $8,649 - $18,871
7,863 Added 1.53%
521,678 $1.1 Million
Q4 2022

Feb 13, 2023

SELL
$1.03 - $1.66 $89 - $144
-87 Reduced 0.02%
513,815 $580,000
Q3 2022

Nov 14, 2022

BUY
$1.31 - $2.48 $3,619 - $6,852
2,763 Added 0.54%
513,902 $837,000
Q2 2022

Aug 12, 2022

SELL
$1.19 - $1.74 $56,050 - $81,955
-47,101 Reduced 8.44%
511,139 $669,000
Q1 2022

May 13, 2022

SELL
$1.61 - $2.31 $2,395 - $3,437
-1,488 Reduced 0.27%
558,240 $898,000
Q4 2021

Feb 11, 2022

BUY
$2.07 - $3.8 $39,044 - $71,675
18,862 Added 3.49%
559,728 $1.16 Million
Q3 2021

Nov 12, 2021

BUY
$2.59 - $4.15 $341,499 - $547,189
131,853 Added 32.24%
540,866 $2.1 Million
Q2 2021

Aug 13, 2021

SELL
$2.07 - $5.1 $490,287 - $1.21 Million
-236,854 Reduced 36.67%
409,013 $1.31 Million
Q1 2021

May 12, 2021

BUY
$1.96 - $2.57 $7,375 - $9,670
3,763 Added 0.59%
645,867 $1.4 Million
Q4 2020

Feb 12, 2021

BUY
$2.24 - $2.87 $106,361 - $136,276
47,483 Added 7.99%
642,104 $1.44 Million
Q3 2020

Nov 13, 2020

BUY
$2.53 - $3.64 $2,330 - $3,352
921 Added 0.16%
594,621 $1.59 Million
Q2 2020

Aug 13, 2020

BUY
$1.66 - $3.15 $53,671 - $101,845
32,332 Added 5.76%
593,700 $1.82 Million
Q1 2020

May 14, 2020

BUY
$1.51 - $3.0 $25,360 - $50,385
16,795 Added 3.08%
561,368 $1.1 Million
Q4 2019

Feb 13, 2020

BUY
$2.79 - $4.32 $206,507 - $319,753
74,017 Added 15.73%
544,573 $1.56 Million
Q3 2019

Nov 12, 2019

BUY
$3.0 - $4.05 $4,479 - $6,046
1,493 Added 0.32%
470,556 $1.73 Million
Q2 2019

Aug 14, 2019

BUY
$3.61 - $5.0 $683,427 - $946,575
189,315 Added 67.67%
469,063 $1.95 Million
Q1 2019

May 14, 2019

BUY
$3.86 - $6.02 $202,931 - $316,489
52,573 Added 23.14%
279,748 $1.43 Million
Q4 2018

Feb 13, 2019

BUY
$3.43 - $5.74 $52,856 - $88,453
15,410 Added 7.28%
227,175 $779,000
Q3 2018

Nov 13, 2018

BUY
$3.68 - $6.93 $33,863 - $63,769
9,202 Added 4.54%
211,765 $1.27 Million
Q2 2018

Aug 14, 2018

BUY
$3.16 - $9.16 $22,600 - $65,512
7,152 Added 3.66%
202,563 $1.29 Million
Q2 2017

Aug 14, 2017

BUY
N/A
195,411
195,411 $480,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $161M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.